Oprelvekin, the energetic factor in NeumegaÂ® is recombinant Interleukin eleven, which is produced in Escherichia coli (E. coli) with the aid of recombinant DNA generation. The protein has a molecular mass of about 19,000 daltons, and is non-glycosylated. The polypeptide is 177 amino acids in duration (the herbal IL-eleven has 178). this variation has no longer ended in measurable differences in bioactivity either in vitro or in vivo. The number one hematopoietic interest of NeumegaÂ® is stimulation of megakaryocytopoiesis and thrombopoiesis. In mice and nonhuman primate studies NeumegaÂ® has proven robust thrombopoietic interest in compromised hematopoiesis, consisting of moderately to seriously myelosuppressed animals. In these studies, NeumegaÂ® advanced platelet nadirs and extended platelet recoveries as compared to controls. In animal research Oprelvekin also has non-hematopoetic sports. This consists of the regulation of intestinal epithelium growth (stronger healing of gastrointestinal lesions), the inhibition of adipogenesis, the induction of acute section protein synthesis (e.g., fibrinogen), and inhibition of macrophageal released pro-inflammatory cytokines.
Oprelvekin is indicated for the prevention of severe thrombocytopenia and the reduction of the need for platelet transfusions following myelosuppressive chemotherapy in adult patients with nonmyeloid malignancies who are at high risk of severe thrombocytopenia. The primary hematopoietic activity of Oprelvekin is stimulation of megakaryocytopoiesis and thrombopoiesis. Oprelvekin has shown potent thrombopoietic activity in individuals with compromised hematopoiesis
Increases reduced platelet levels due to chemotherapy
Oprelvekin binds to the interleukin 11 receptor which leads to a cascade of signal transduction events. IL-11 is a thrombopoietic growth factor that directly stimulates the proliferation of hematopoietic stem cells and megakaryocyte progenitor cells and induces megakaryocyte maturation resulting in increased platelet production.